Is ravulizumab the new treatment of choice for atypical hemolytic uremic syndrome (aHUS)?
Where this comes from
- Record sourced from PubMed, PMID 32444092.
- Also identified by DOI 10.1016/j.kint.2020.03.011.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Ravulizumab, a new long-acting C5 inhibitor, recently received FDA approval for the treatment of aHUS. Rates of complete thrombotic microangiopathy response were similar to those observed in major eculizumab trials; however, fewer patients in the ravulizumab study were able to stop dialysis, probably due to differences in the study populations. Until additional data/analyses are available, eculizumab remains the drug of choice for an acute aHUS episode, whereas ravulizumab has several advantages in maintenance treatment.
Medical subject headings
- Atypical Hemolytic Uremic Syndrome